Parkwalk’s focused investment strategy, combined with its highly experienced and deep network of partners, specialist co-investors, industry experts and advisors, allows the team to make relatively rapid investment decisions, and deploy capital efficiently.
Parkwalk’s focused asset class has enabled us to develop strong and trusted relationships over the past 10 years, building a reputation as good people to do business with, and bringing with it the highest quality deal-flow.
We are the most co-invested fund in this asset class and we invest c.£65m per year into the sector.
Parkwalk actively seeks to co-invest with other specialist funds
We have the ability to invest from £250k to £10m per round
Invest from early-stage through to Series C round and beyond
Look to follow our money and invest over multiple rounds
Key Parkwalk investment philosophy
- We are willing to take early stage risk but invest across the spectrum from seed to later stage opportunities
- We seek to invest in flat capital structures with all stakeholders (investors, founders, institutions etc) aligned in the same share class
- We feel that by investing we are showing the founders and management respect for their business plan and vision and we expect this to be reciprocated
- We feel these investments are a team effort between all the stakeholders and that moving forward they should all be treated fairly
- We look to follow our money and will invest over multiple rounds
- We have the ability to invest from £250k to £10m in any one round depending on the stage of the business
Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.
Quethera is a gene therapy company developing a novel treatment for glaucoma. The company targeted delivering gene products for neuroprotectants and their receptors directly to the eye. This could provide long term neuroprotection to the retinal ganglion cells (RGC) in the eye, preventing their death and visual field loss.
Through the use of gene editing and gene modulation technologies, Horizon provides a wide range of products and services to customers across the life sciences based on the development of cell-based models and their application. Horizon’s powerful gene editing platform develops genetically engineered cell models which are used to understand the role of genomics in
Oxtex is an early-stage medical device company which has developed a novel self-inflating tissue expander for the use in reconstructive surgery. The device is implanted underneath the skin close to the repair site, where it will slowly expand in one direction causing the skin to grow which can then be used in the reconstruction.